References
- 대한내분비학회. 골다공증 진단 및 치료지침 2007. 대한내분비학회지. 2008; 23(2):76.
- Canalis E. Mechanisms of Glucocorticoid action in Bone. Implications to glucocorticoid-induced osteoporosis. J Clion Endocri Met. 1996;81:3441-7. https://doi.org/10.1210/jc.81.10.3441
- Pietschmann P et al. Osteoporosis, an age-related and gender-specific disease. Gerontology. 2008;55(1):3-12. https://doi.org/10.1159/000166209
- Pacifici R. Estrogen deficiency, T cells and bone loss. Cell Immunol. 2008; 252(1-2):68-80. https://doi.org/10.1016/j.cellimm.2007.06.008
- Kumamoto H et al. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand(RANKL) and osteoclastogenesis inhibitory factor(OCIF) /osteoprotegerin(OPG) in ameloblastomas. J. Oral Pathol. Med. 2004;33(1):46-52. https://doi.org/10.1111/j.1600-0714.2004.00204.x
- Reddy SV. Regulatory mechanisms operative in osteoclasts. Crit Rev. Eukaryot Gene Expr. 2004;14(4):255-70. https://doi.org/10.1615/CritRevEukaryotGeneExpr.v14.i4.20
- Boyce BF et al. Roles for NFkappaB and c-Fos in osteoclasts. J Bone Miner Metab. 2005;23:11-5. https://doi.org/10.1007/BF03026317
- Murakami A et al. Phenethyl isothiocyanate suppreases receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis by blocking activation of ERK1/2 and p38 MAPK in RAW264.7 macrophages. Biofactors. 2007;30(1) :1-11. https://doi.org/10.1002/biof.5520300101
- Pang M et al. AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells. Gene. 2007;403(1-2):151-8. https://doi.org/10.1016/j.gene.2007.08.007
- Lee ZH et al. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 2003;305(2) :211-4. https://doi.org/10.1016/S0006-291X(03)00695-8
- 王氷注. 黃帝內經素問. 서울:大成出版社. 1986:21, 101, 212, 274, 340, 768.
- 이응세 등. 골다공증의 동의학적 임상문헌에 관한 고찰. 한방재활의학회지. 1997:7(1):437-56.
- 藏位壓. 王和鳴編:中國骨病學. 北京:人民衛生出版社1990:249-58.
- 陳可培. 中國傳統康復醫學. 北京:人民衛生出版社. 1998:555-8.
- 蔡新吉. 腎虛證與骨廣物含量的關係. 山東:山東中醫學院學報. 1992:16(2):52.
- 呂犱政. 常見丙最新療法. 北京:中國中醫學出版社. 1994:371-3.
- 한방재활의학과학회. 한방재활의학. 군자출판사. 2003:110, 168.
- 정재숙. 生血補髓湯이 난소적출 흰쥐 대퇴골의 형태계측학적 변화 및 골대사 관련 인자에 미치는 영향. 世明大學校大學院, 2005.
- 金根模. 鹿茸및 六味地黃湯加鹿茸이 白鼠의 運動抑制性골다공증에 미치는 影響, 慶山大學校大學院. 1994.
- 朴鍾徹. 左歸飮과 右歸飮이 卵巢摘出白鼠의 性호르몬과 脂質및 骨代謝에 미치는 影響. 大韓韓方婦人科學會誌.1995;8(1):1-27.
- 李相坤. 四物湯과 六味地黃湯이 卵巢摘出로 誘導된 白鼠의 골다공증에 미치는 影響. 慶山大學校大學院, 1996.
- 曺永任. 借力丸變方이 卵巢摘出로 誘導된 白鼠의 골다공증에 미치는 影響. 大田大學校大學院, 1999.
- 전국한의과대학본초학교수. 본초학. 서울:영림사, 2000:307.
- 안덕균. 한국본초도감. 서울:교학사.1999:304.
- 한방약리학교재편찬위원회. 한방약리학. 서울:신일상사. 2005:201, 202.
- 송승원. 威靈仙이 류마토이드 관절염 환자에서 분리한 활액세포의 면역반응에 미치는 영향. 大田大學校大學院.2003.
- 유석. 威靈仙이 관절염 유발 동물모델의 소염, 진통 및 해열작용에 미치는 영향. 東國大學校大學院. 2004.
- 대한 병리학회. 병리학. 서울:고문사 1991:1183-5.
- 徐舞圭. 成人病老人醫學서울:고려의학. 1993:483-6.
- 민헌기. 임상 내분비학. 서울:고려의학. 1990:220-2, 415-21, 489-98.
- 杜鎬京. 東醫腎系學. 서울:東洋醫學硏究院. 1992:578-84, 1240-53.
- 羅元愷. 中醫婦科學. 河北省:人民衛生出版社. 1988:17-22, 161-3.
- 陳自明. 婦人良方大全1卷. 文光圖書有限公司. 1987:38.
- 葉天士. 葉天士女科. 서울:大星文化社. 1989:212, 213.
- 최영길. 내분비학. 의학출판사. 1994:483-90, 573-80.
- 김영설. 골다공증의 약물치료. 제44회 대한내과학회 추계학회지. 1992:50-3.
- Meiyanto E et al. Osteoclast differentiation factor modulates cell cycle machinery and causes a delay in s phase progression in RAW 264.7 cells. Biochem. Biophys. Res. Commun. 2001:282(1):278-83. https://doi.org/10.1006/bbrc.2001.4564
- John T et al. Parathyroid hormone -dependent signaling pathways regulating genes in bone cells, Gene. 2002; 282(1-2):1-17. https://doi.org/10.1016/S0378-1119(01)00798-3
- Cho ES et al.. Rolipram, a phosphodiesterase 4 inhibitor, stimulates osteoclast formation by inducing TRANCE expression in mouse calvarial cells. Arch. Pharm. Res. 2004;27(12):1258-62. https://doi.org/10.1007/BF02975891
- Khosla S. Minireview. the OPG/ RANKL/RANK system. Endocrinology. 2001;142(12):5050-5. https://doi.org/10.1210/en.142.12.5050
- Gallea S et al. Activation of mitogen -activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2, C12 cells, Bone. 2001;28(5):491-8. https://doi.org/10.1016/S8756-3282(01)00415-X
- Yao Z et al. Tumor necrosis factor -alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through upregulation of c-Fos expression, J. Biol. Chem. 2006;281(17):11846-55. https://doi.org/10.1074/jbc.M512624200
- Liu XH et al. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/ RANKL/RANK system, Ann NY. Acad. Sci. 2006;1068:225-33. https://doi.org/10.1196/annals.1346.047
- Lin TH et al. PPAR gamma inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats, Bone. 2007;41(4):562-74. https://doi.org/10.1016/j.bone.2007.06.017
- Zheng H et al. Collin Osdoby P.. RANKL stimulates inducible nitric -oxide synthetase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKLinduced interferon-beta via NF-kappa B that restrains osteoclastogenesis and bone resorption, J. Biol. Chem. 2006:281(23):15809-20. https://doi.org/10.1074/jbc.M513225200
- Matsumoto M et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1, J. Biol. Chem. 2004:279(44):45969-79.